Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

References

• Al-Bari, M., and A. Alim. 2017. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol. Res. Pers. 5:1–13. doi:10.1002/prp2.293.
   Web of Science ®Google Scholar
• Cabral, R. T. S., E. M. Klumb, M. I. N. N. Couto, and S. Carneiro. 2019. Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography. Arq. Bras. Oftalmol. 82:12–17. doi:10.5935/0004-2749.20190002.
   PubMed Web of Science ®Google Scholar
• Castrejón, I., C. Tani, M. Jolly, A. Huang, and M. Mosca. 2014. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin. Exp. Rheumatol. 32 (5 Suppl 85):S85–S95.
   PubMed Web of Science ®Google Scholar
• Chatre, C., F. Roubille, H. Vernhet, C. Jorgensen, and Y. M. Pers. 2018. Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf. 41:919–31. doi:10.1007/s40264-018-0689-4.
   PubMed Web of Science ®Google Scholar
• Gossec, L., A. Molto, X. Romand, D. Puyraimond-Zemmour, M. Lavielle, C. Beauvais, E. Senbel, R. M. Flipo, S. Pouplin, C. Richez, et al. 2019. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Joint Bone Spine 86:13–19. doi:10.1016/j.jbspin.2018.08.006.
   PubMed Web of Science ®Google Scholar
• Guo, X., J. E. Seo, X. Li, and N. Mei. 2020. Genetic toxicity assessment using liver cell models: Past, present, and future. J. Toxicol. Environ. Health B 23:27–50. doi:10.1080/10937404.2019.1692744.
   PubMed Web of Science ®Google Scholar
• Jorge, A., C. Ung, L. H. Young, R. B. Melles, and H. K. Choi. 2018. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nature Rev. Rheumatol. 14:693–703. doi:10.1038/s41584-018-0111-8.
   PubMed Web of Science ®Google Scholar
• Kalia, S., and J. P. Dutz. 2007. New concepts in antimalarial use and mode of action in dermatology. Dermatol. Ther. 2:160–74. doi:10.1111/j.1529-8019.2007.00131.x.
   Google Scholar
• Liu, D., X. Li, Y. Zhang, J. S. Kwong, L. Li, Y. Zhang, C. Xu, Q. Li, X. Sun, H. Tian, et al. 2018. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and meta-analysis. Drug Des. Dev. Ther. 11:1685–95. doi:10.2147/DDDT.S166893.
   Google Scholar
• Liu, J., R. Cao, M. Xu, X. Wang, H. Zhang, H. Hu, Y. Li, Z. Hu, W. Zhong, and M. Wang. 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Dis. 18:16. doi:10.1038/s41421-020-0156-0.
   Google Scholar
• Marmor, M. F., R. E. Carr, M. Easterbrook, and W. F. Mieler, American Academy of Ophthalmology. 2002. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology. Ophthalmology 109:1377–82. doi:10.1016/S0161-6420(02)01168-5.
   PubMed Web of Science ®Google Scholar
• Marmor, M.F., Kellner, U., Lai, T.Y., Melles, R.B., Mieler, W.F., American Academy of Ophthalmology. 2016. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 123: 1386–94. doi:10.1016/j.ophtha.2016.01.058.
   PubMed Web of Science ®Google Scholar
• Mavrikakis, I., P. P. Sfikakis, E. Mavrikakis, K. Rougas, A. Nikolaou, C. Kostopoulos, and M. Mavrikakis. 2003. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: A reappraisal. Ophthalmology 110:1321–26. doi:10.1016/S0161-6420(03)00409-3.
   PubMed Web of Science ®Google Scholar
• Melles, R. B., and M. F. Marmor. 2014. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. J. Am. Med. Assoc. Ophthalmol. 132:1453–60.
   PubMed Web of Science ®Google Scholar
• Melles, R. B., and M. F. Marmor. 2015. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122:110–16. doi:10.1016/j.ophtha.2014.07.018.
   PubMed Web of Science ®Google Scholar
• Plantone, D., and T. Koudriavtseva. 2018. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: A mini-review. Clin. Drug Investig. 38:653–71. doi:10.1007/s40261-018-0656-y.
   PubMed Web of Science ®Google Scholar
• Rainsford, K. D., A. L. Parke, M. Clifford-Rashotte, and W. F. Kean. 2015. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23:231–69.
   PubMed Web of Science ®Google Scholar
• Riccio, E. S., P. S. Lee, R. A. Winegar, D. J. Krogstad, D. De, and J. C. Mirsalis. 2001. Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. Environ. Mol. Mutagen. 38:69–79. doi:10.1002/em.1052.
   PubMed Web of Science ®Google Scholar
• Stein, M., M. J. Bell, and L. C. Ang. 2000. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27:2927–31.
   PubMed Web of Science ®Google Scholar
• Stokkermans, T. J., and G. Trichonas. 2019. Chloroquine and Hydroxychloroquine Toxicity. Stat Pearls. Stat Pearls Publishing, LLC. 10. Gen 22; NBK 537086
   Google Scholar
• Touret, F., and X. de Lamballerie. 2020. Of chloroquine and COVID-19. Antiviral Res. 177:104762. doi:10.1016/j.antiviral.2020.104762.
   PubMed Web of Science ®Google Scholar
• Wolfe, F., and M. F. Marmor. 2010. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62:775–84. doi:10.1002/acr.20133.
   PubMed Web of Science ®Google Scholar
• Yam, J. C., and A. K. Kwok. 2006. Ocular toxicity of hydroxychloroquine. Hong Kong Med. J. 12:294–304.
   PubMedGoogle Scholar
• Yogasundaram, H., B. N. Putko, J. Tien, D. I. Paterson, B. Cujec, J. Ringrose, and G. Y. Oudit. 2014. Hydroxychloroquine-induced cardiomyopathy: Case report, pathophysiology, diagnosis, and treatment. Can. J. Cardiol. 30:1706–15. doi:10.1016/j.cjca.2014.08.016.
   PubMed Web of Science ®Google Scholar
• Zhang, C., S. Huang, F. Zheng, and Y. Dai. 2020. Controversial treatments: An updated understanding of the Coronavirus Disease 2019. J. Med. Virol. doi:10.1002/jmv.25788. Epub ahead of print.
   Web of Science ®Google Scholar
• Zhang, Y., Z. Liao, L. J. Zhang, and H. T. Xiao. 2015. The utility of chloroquine in cancer therapy. Curr. Med. Res. Opin. 31:1009–13. doi:10.1185/03007995.2015.1025731.
   PubMed Web of Science ®Google Scholar